187 related articles for article (PubMed ID: 8471431)
1. Cisplatin-DNA damage recognition proteins in human tumour extracts.
Bissett D; McLaughlin K; Kelland LR; Brown R
Br J Cancer; 1993 Apr; 67(4):742-8. PubMed ID: 8471431
[TBL] [Abstract][Full Text] [Related]
2. Binding activities of cis-platin-damage-recognition proteins in human tumour cell lines.
McLaughlin K; Coren G; Masters J; Brown R
Int J Cancer; 1993 Feb; 53(4):662-6. PubMed ID: 8436440
[TBL] [Abstract][Full Text] [Related]
3. Binding of human single-stranded DNA binding protein to DNA damaged by the anticancer drug cis-diamminedichloroplatinum (II).
Clugston CK; McLaughlin K; Kenny MK; Brown R
Cancer Res; 1992 Nov; 52(22):6375-9. PubMed ID: 1423284
[TBL] [Abstract][Full Text] [Related]
4. Proteins binding to cisplatin-damaged DNA in human cell lines.
Billings PC; Engelsberg BN; Hughes EN
Cancer Invest; 1994; 12(6):597-604. PubMed ID: 7994594
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms associated with the expression of cisplatin resistance in a human ovarian tumor cell line following exposure to fractionated X-irradiation in vitro.
Dempke WC; Shellard SA; Hosking LK; Fichtinger-Schepman AM; Hill BT
Carcinogenesis; 1992 Jul; 13(7):1209-15. PubMed ID: 1638688
[TBL] [Abstract][Full Text] [Related]
6. Pretreatment with 5-fluorouracil enhances cytotoxicity and retention of DNA-bound platinum in a cisplatin resistant human ovarian cancer cell line.
Tanaka T; Masuda H; Naito M; Tamai H
Anticancer Res; 2001; 21(4A):2463-9. PubMed ID: 11724308
[TBL] [Abstract][Full Text] [Related]
7. Gene expression in X-irradiated human tumour cell lines expressing cisplatin resistance and altered DNA repair capacity.
Taverna P; Hansson J; Scanlon KJ; Hill BT
Carcinogenesis; 1994 Sep; 15(9):2053-6. PubMed ID: 7923602
[TBL] [Abstract][Full Text] [Related]
8. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines.
Mamenta EL; Poma EE; Kaufmann WK; Delmastro DA; Grady HL; Chaney SG
Cancer Res; 1994 Jul; 54(13):3500-5. PubMed ID: 8012973
[TBL] [Abstract][Full Text] [Related]
9. Detection of proteins that recognize platinum-modified DNA using gel mobility shift assay.
Fujiwara Y; Kasahara K; Sugimoto Y; Nishio K; Ohmori T; Saijo N
Jpn J Cancer Res; 1990 Dec; 81(12):1210-3. PubMed ID: 2125989
[TBL] [Abstract][Full Text] [Related]
10. Correlation between cell killing by cis-diamminedichloroplatinum(II) in six mammalian cell lines and binding of a cis-diamminedichloroplatinum(II)-DNA antiserum.
Terheggen PM; Emondt JY; Floot BG; Dijkman R; Schrier PI; den Engelse L; Begg AC
Cancer Res; 1990 Jun; 50(12):3556-61. PubMed ID: 2340504
[TBL] [Abstract][Full Text] [Related]
11. Correlation of the response to cisplatin of human ovarian cancer cell lines, originating from one tumor but with different sensitivity, with the recovery of DNA adducts.
De Pooter CM; Van Oosterom AT; Scalliet PG; Maes RA; de Bruijn EA
Biochem Pharmacol; 1996 Mar; 51(5):629-34. PubMed ID: 8615899
[TBL] [Abstract][Full Text] [Related]
12. Characterization of binding proteins from ovarian carcinoma and kidney tubule cells that are specific for cisplatin modified DNA.
Andrews PA; Jones JA
Cancer Commun; 1991 Mar; 3(3):93-102. PubMed ID: 2001331
[TBL] [Abstract][Full Text] [Related]
13. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
Schmidt W; Chaney SG
Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
[TBL] [Abstract][Full Text] [Related]
14. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts.
Vaisman A; Varchenko M; Umar A; Kunkel TA; Risinger JI; Barrett JC; Hamilton TC; Chaney SG
Cancer Res; 1998 Aug; 58(16):3579-85. PubMed ID: 9721864
[TBL] [Abstract][Full Text] [Related]
15. Increased expression of thioredoxin/adult T-cell leukemia-derived factor in cisplatin-resistant human cancer cell lines.
Yamada M; Tomida A; Yoshikawa H; Taketani Y; Tsuruo T
Clin Cancer Res; 1996 Feb; 2(2):427-32. PubMed ID: 9816187
[TBL] [Abstract][Full Text] [Related]
16. cis-Diamminedichloroplatinum-resistant cell lines derived from human epithelial ovarian carcinoma express increased susceptibility to angiogenesis inhibitor TNP-470.
Tamura M; Takakuwa K; Tanaka K
Gynecol Oncol; 2004 Feb; 92(2):530-6. PubMed ID: 14766244
[TBL] [Abstract][Full Text] [Related]
17. DNA binding activities of p53 protein following cisplatin damage of ovarian cells.
Wetzel CC; Berberich SJ
Oncol Res; 1998; 10(3):151-61. PubMed ID: 9700726
[TBL] [Abstract][Full Text] [Related]
18. Localization of the binding region of high mobility group protein 2 to cisplatin-damaged DNA.
Lawrence DL; Engelsberg BN; Farid RS; Hughes EN; Billings PC
J Biol Chem; 1993 Nov; 268(32):23940-5. PubMed ID: 8226934
[TBL] [Abstract][Full Text] [Related]
19. Lactacystin enhances cisplatin sensitivity in resistant human ovarian cancer cell lines via inhibition of DNA repair and ERCC-1 expression.
Li QQ; Yunmbam MK; Zhong X; Yu JJ; Mimnaugh EG; Neckers L; Reed E
Cell Mol Biol (Noisy-le-grand); 2001; 47 Online Pub():OL61-72. PubMed ID: 11936875
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a cisplatin-resistant human ovarian carcinoma cell line expressing cross-resistance to 5-fluorouracil but collateral sensitivity to methotrexate.
Hill BT; Shellard SA; Hosking LK; Dempke WC; Fichtinger-Schepman AM; Tone T; Scanlon KJ; Whelan RD
Cancer Res; 1992 Jun; 52(11):3110-8. PubMed ID: 1591724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
